Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry

Michael Haft; Keith Knapp; Ami Claxton; Breda Munoz; Sanjeev Balu; Shannon Schnieder; Jonathan Silverberg; Diamant Thaci; Lawrence Eichenfield

doi:10.25251/skin.7.supp.149

Michael Haft
Keith Knapp

a:1:{s:5:"en_US";s:10:"Target RWE";}

Ami Claxton
Breda Munoz
Sanjeev Balu
Shannon Schnieder
Jonathan Silverberg
Diamant Thaci
Lawrence Eichenfield

Keywords

Atopic Dermatitis, Registry, Target RWE, Advanced Systemic Therapy, vIGA-AD, Treatment, Naive, POEM, BSA

References

1. Nutten, S., Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab, 2015. 66 Suppl 1: p. 8-16.

2. AD Langan SM, Irvine AD, Weidinger S. Lancet. 2020 Aug 1;396(10247):345-360.

3. Abuabara, K. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGETDERM AD study design and rational BMJ Open 2020;10:e0399282020.

Poster PDF

Published

Mar 13, 2023

DOI https://doi.org/10.25251/skin.7.supp.149

How to Cite

Haft, M., Knapp, K., Claxton, A., Munoz, B., Balu, S., Schnieder, S., Silverberg, J., Thaci, D., & Eichenfield, L. (2023). Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry. SKIN The Journal of Cutaneous Medicine, 7(2), s149. https://doi.org/10.25251/skin.7.supp.149

Issue

Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

Section

Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Andrew Blauvelt, Diamant Thaci, Kim Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Jenny Yu, Ya-Wen Yang, Jeffrey Crowley, Peter Foley, Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Lawrence Eichenfeld, Jonathan Silverberg, Robert Bissonnette, Anna Tallman, David Rubenstein, Stephen Piscitelli, John Jett, Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Richard Langley, Diamant Thaci, Andrew Blauvelt, Tsen-Fang Tsai, Megan Miller, Jenny Yu, Yaung-Kaung Shen, Yin You, Ya-Wen Yang, Kim Papp, Luis Puig, Peter Foley, Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Eric Simpson, Joseph Merola, Jonathan Silverberg, Rebecca Zachariae, Rebecca Olsen, Andreas Wollenberg, Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt, Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt, Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Stephan Weidinger, Jonathan Silverberg, Darryl Toth, Thomas Bieber, Andrew Alexis, Boni Elewski, Andrew Pink, DirkJan Hignen, Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Andrew Blauvelt, Jacek Szepietowski, Kim Papp, Eric Simpson, Jonathan Silverberg, Brian Kim, Shawn Kwatra, Michael Kuligowski, May Venturanza, Kang Sun, Leon Kircik, Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 3 4 5 6 7 > >>

Main Article Content

Keywords

References

Article Sidebar

Article Details

Most read articles by the same author(s)